The structural basis for amyloid formation by plasma apolipoproteins: A review

European Biophysics Journal

Volumn 31, Issue 1, 2002, Pages 2-8

  Hatters, Danny M ^a   Howlett, Geoffrey J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Amphipathic helix; Amyloid; Apolipoproteins; Atherosclerosis; Conformational stability

Indexed keywords

AMYLOID; AMYLOID A PROTEIN; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C2; APOLIPOPROTEIN E; GUANIDINE; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; CONFERENCE PAPER; CREUTZFELDT JAKOB DISEASE; HUMAN; LIPOPROTEIN BLOOD LEVEL; PARKINSON DISEASE; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

AMYLOID; APOLIPOPROTEIN C-II; APOLIPOPROTEINS; APOLIPOPROTEINS C; BINDING SITES; BIOPHYSICS; DRUG STABILITY; HUMANS; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY;

EID: 0036520326     PISSN: 01757571     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002490100172     Document Type: Conference Paper

References (70)

1. Aggerbeck LP, Wetterau JR, Weisgraber KH, Wu CS, Lindgren FT (1988) Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxy-terminal domains. J Biol Chem 263:6249-6258
2. Anantharamaiah GM, Jones JL, Brouillette CG, Schmidt CF, Chung BH, Hughes TA, Bhown AS, Segrest JP (1985) Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoylphosphatidylcholine. J Biol Chem 260:10248-10255
3. Benson MD, Liepnieks JJ, Yazaki M, Yamashita T, Hamidi Asl K, Guenther B, Kluve-Beckerman B (2001) A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics 72:272-277
4. Booth DR, Tan SY, Booth SE, Hsuan JJ, Totty NF, Nguyen O, Hutton T, Vigushin DM, Tennent GA, Hutchinson WL, et al. (1995) A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. Q J Med 88:695-702
5. Booth DR, Tan SY, Booth SE, Tennent GA,-Hutchinson WL, Hsuan JJ, Totty NF, Truong O, Soutar AK, Hawkins PN, Bruguera M, Caballeria J, Sole M, Campistol JM, Pepys MB (1996) Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein A1 gene. J Clin Invest 97:2714-2721
6. Booth DR, Sunde M, Bellotti V, Robinson CV, Hutchinson WL, Fraser PE, Hawkins PN, Dobson CM, Radford SE, Blake CC, Pepys MB (1997) Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385:787-793
7. Castano EM, Prelli F, Pras M, Frangione B (1995) Apolipoprotein E carboxy-terminal fragments are complexed to amyloids A and L. Implications for amyloidogenesis and Alzheimer's disease. J Biol Chem 270:17610-17615
8. Chiti F, Webster P, Taddei N, Clark A, Stefani M, Ramponi G, Dobson CM (1999) Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci USA 96:3590-3594
9. Choo-Smith LP, Garzon-Rodriguez W, Glabe CG, Surewicz WK. (1997) Acceleration of amyloid fibril formation by specific binding of Aβ-(1-40) peptide to ganglioside-containing membrane vesicles. J Biol Chem 272:22987-22990
10. Conway KA, Harper JD, Lansbury PT (1998) Accelerated in vitro fibril formation by a α-synuclein linked to early-onset Parkinson disease. Nat Med 4:1318-1320
11. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97:571-586
12. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923
13. Davidson WS, Jonas A, Clayton DF, George JM (1998) Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273:9443-9449
14. Dobson CM (1999) Protein misfolding, evolution and disease. Trends Biochem Sci 24:329-332
15. Eliezer D, Kutluay E, Bussell R, Browne G (2001) Conformational properties of α-synuclein in its free and lipid-associated states. J Mol Biol 307:1061-1073
16. Fisher WR, Taniuchi H, Anfinsen CB (1973) On the role of heme in the formation of the structure of cytochrome C. J Biol Chem 248:3188-3195
17. Fu S, Davies MJ, Stocker R, Dean RT (1998) Evidence for roles of radicals in protein oxidation in advanced human atherosclerotic plaque. Biochem J 333:519-525
18. Gamblin TC, King ME, Kuret J, Berry RW, Binder LI (2000) Oxidative regulation of fatty acid-induced tau polymerization. Biochemistry 39:14203-14210
19. Genschel J, Haas R, Propsting MJ, Schmidt HH (1998) Apolipo protein A-1 induced amyloidosis. FEBS Lett 430:145-149
20. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290:985-989
21. Goda S, Takano K, Yamagata Y, Nagata R, Akutsu H, Maki S, Namba K, Yutani K (2000) Amyloid protofilament formation of hen egg lysozyme in highly concentrated ethanol solution. Protein Sci 9:369-375
22. Gursky O, Atkinson D (1996a) Thermal unfolding of human high-density apolipoprotein A-1: implications for a lipid-free molten globular state. Proc Natl Acad Sci USA 93:2991-2995
23. Gursky O, Atkinson D (1996b) High- and low-temperature unfolding of human high-density apolipoprotein A-2. Protein Sci 5:1874-1882
24. Gursky O, Atkinson D (1998) Thermodynamic analysis of human plasma apolipoprotein C-1: high-temperature unfolding and low-temperature oligomer dissociation. Biochemistry 37:1283-1291
25. Hamidi Asl K, Liepnieks JJ, Nakamura M, Parker F, Benson MD (1999a) A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis. Biochem Biophys Res Commun 257:584-588.
26. Hamidi Asl L, Liepnieks JJ, Hamidi Asl K, Uemichi T, Moulin G, Desjoyaux E, Loire R, Delpech M, Grateau G, Benson MD (1999b) Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein Al. Am J Pathol 154:221-227
27. Hatters DM, MacPhee CE, Lawrence LJ, Sawyer WH, Howlett GJ (2000) Human apolipoprotein C-II forms twisted amyloid ribbons and closed loops. Biochemistry 39:8276-8283
28. Hatters DM, Lawrence LJ, Howlett GJ (2001) Sub-micellar phospholipid accelerates amyloid formation by apolipoprotein C-II. FEBS Lett 494:220-224
29. Higuchi K, Kitagawa K, Naiki H, Hanada K, Hosokawa M, Takeda T (1991) Polymorphism of apolipoprotein A-Il (apoA-II) among inbred strains of mice. Relationship between the molecular type of apoA-II and mouse senile amyloidosis. Biochem J 279:427-433
30. Husebekk A, Skogen B, Husby G, Marhaug G (1985) Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand J Immunol 21:283-287
31. Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M (1998) Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem 273:26292-26294
32. Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE (2000) α-Synuclein membrane interactions and lipid specificity. J Biol Chem 275:34328-34334
33. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733-736
34. Kelly JW (1996) Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 6:11-17
35. Li WH, Tanimura M, Luo CC, Datta S, Chan L (1988) The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships, and evolution. J Lipid Res 29:245-271
36. MacPhee CE, Dobson CM (2000) Formation of mixed fibrils demonstrates the generic nature and potential utility of amyloid nanostructures. J Am Chem Soc 122:12707-12713
37. 2-microglobulin and amyloid formation in vitro. Biochemistry 39:8735-8746
38. Morrisett JD, Jackson RL, Gotto AM Jr (1977) Lipid-protein interactions in the plasma lipoproteins. Biochim Biophys Acta 472:93-133
39. Mucchiano G, Cornwell GG III, Westermark P (1992) Senile aortic amyloid. Evidence for two distinct forms of localized deposits. Am J Pathol 140:871-877
40. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K (1991) Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541:163-166
41. Naslund J, Thyberg J, Tjernberg LO, Wernstedt C, Karlstrom AR, Bogdanovic N, Gandy SE, Lannfelt L, Terenius L, Nordstedt C (1995) Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain. Neuron 15:219-228
42. Nettleton EJ, Sunde M, Lai Z, Kelly JW, Dobson CM, Robinson CV (1998) Protein subunit interactions and structural integrity of amyloidogenic transthyretins: evidence from electrospray mass spectrometry. J Mol Biol 281:553-564
43. Nichols WC, Dwulet FE, Liepnieks J, Benson MD (1988) Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. Biochem Biophys Res Commun 156:762-768
44. 174→Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. Am J Pathol 155:695-702
45. O'Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, Hudkins K, Wight TN, Chait A (1998) Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 98:519-527
46. Perrin RJ, Woods WS, Clayton DF, George JM (2000) Interaction of human α-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J Biol Chem 275:34393-34398
47. Persey MR, Booth DR, Booth SE, van Zyl-Smit R, Adams BK, Fattaar AB, Tennent GA, Hawkins PN, Pepys MB (1998) Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. Kidney Int 53:276-281
48. Perugini MA, Schuck P, Howlett GJ (2000) Self-association of human apolipoprotein E3 and E4 in the presence and absence of phospholipid. J Biol Chem 275:36758-36765
49. Rankin SE, Watts A, Pinheiro TJ (1998) Electrostatic and hydrophobic contributions to the folding mechanism of apocytochrome C driven by the interaction with lipid. Biochemistry 37:12588-12595
50. Segrest JP, Garber DW, Brouillette CG, Harvey SC, Anantharamaiah GM (1994) The amphipathic α-helix: a multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem 45:303-369
51. Serpell LC, Sunde M, Benson MD, Tennent GA, Pepys MB, Fraser PE (2000) The protofilament substructure of amyloid fibrils. J Mol Biol 300:1033-1039
52. Sipe JD (1992) Amyloidosis. Annu Rev Biochem 61:947-975
53. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G (2000) Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 1502:139-144
54. Soulages JL, Bendavid OJ (1998) The lipid binding activity of the exchangeable apolipoprotein apolipophorin-III correlates with the formation of a partially folded conformation. Biochemistry 37:10203-10210
55. Sousa MM de, Vital C, Ostler D, Fernandes R, Pouget-Abadie J, Carles D, Saraiva MJ (2000) Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol 156:1911-1917
56. Soutar AK, Hawkins PN, Vigushin DM, Tennent GA, Booth SE, Hutton T, Nguyen O, Totty NF, Feest TG, Hsuan JJ, et al. (1992) Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci USA 89:7389-7393
57. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD (1993) Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:9098-9102
58. Suarna C, Dean RT, May J, Stocker R (1995) Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of α-tocopherol and ascorbate. Arterioscler Thromb Vasc Biol 15:1616-1624
59. Sunde M, Blake C (1997) The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv Protein Chem 50:123-159
60. Tajima S, Yokoyama S, Kawai Y, Yamamoto A (1982) Behavior of apolipoprotein C-II in an aqueous solution. J Biochem (Tokyo) 91:1273-1279
61. Takahashi Y, Ueno A, Mihara H (1999) Optimization of hydrophobic domains in peptides that undergo transformation from α-helix to β-fibril. Bioorg Med Chem 7:177-185
62. Terzi E, Holzemann G, Seelig J (1997) Interaction of Alzheimer β-amyloid peptide (1-40) with lipid membranes. Biochemistry 36:14845-14852
63. Uhlar CM, Whitehead AS (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265:501-523
64. Weinberg RB, Spector MS (1985) Structural properties and lipid binding of human apolipoprotein A-IV. J Biol Chem 260:4914-4921
65. Westermark P, Mucchiano G, Marthin T, Johnson KH, Sletten K (1995) Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Am J Pathol 147:1186-1192
66. Wetterau JR, Aggerbeck LP, Rall SC Jr, Weisgraber KH (1988) Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem 263:6240-6248
67. Williams J, Tabas I (1995) The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15:551-561
68. Wilson DM, Binder LI (1997) Free fatty acids stimulate the polymerization of tau and amyloid β peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am J Pathol 150:2181-2195
69. Wisniewski T, Golabek AA, Kida E, Wisniewski KE, Frangione B (1995a) Conformational mimicry in Alzheimer's disease. Am J Pathol 147:238-244
70. Wisniewski T, Lalowski M, Golabek A, Vogel T, Frangione B (1995b) Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet 345:956-958